Drug updated on 4/17/2024
| Dosage Form | Injection (intramuscular: 10 mg/6 ml, 20 mg/6ml, 30 mg/6ml) |
| Drug Class | Somatostatin analogs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For acromegaly.
- For severe diarrhea/flushing episodes associated with metastatic carcinoid tumors.
- For profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors.
Summary
- Octreotide acetate (Sandostatin LAR Depot) is used for the treatment of acromegaly, severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, and profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors.
- Three systematic reviews/meta-analyses were reviewed that discussed the use and effectiveness of octreotide acetate in various clinical scenarios.
- One review evaluated the efficiency of octreotide in stopping post-surgical Chyle Leak in neck dissection patients, finding it to be an effective way to manage this complication when combined with primary treatment.
- Another study examined its role when combined with other therapies such as everolimus or Peptide Receptor Radionuclide Therapy for neuroendocrine neoplasia management; disease control was observed in 85% cases while progression free survival ranged from 15 to 16.4 months and overall survival from 25 to 61.9 months.
- The third study compared octreotide's effectiveness against oral dietary modification (ODM) for managing chylous fistulae following neck surgery; no significant difference was found between both methods regarding time taken until resolution or rate of spontaneous resolution without need for surgery.
- Across all studies reviewed, Sandostatin LAR Depot showed a good safety profile being well-tolerated by patients experiencing few mild side effects not requiring drug withdrawal; however more robust randomized controlled trials are needed to confirm these findings across different patient populations and indications.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Sandostatin LAR Depot (octreotide acetate) Prescribing Information. | 2023 | Novartis Pharmaceuticals Corporation East Hanover, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Effect of octreotide in stopping post surgical chyle leak in neck dissection-a systematic review. | 2022 | Journal of Oral Biology and Craniofacial Research |
| Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. | 2021 | Journal of Gastrointestinal Oncology |
| Octreotide versus oral dietary modification for the treatment of chylous fistula following neck dissection: a systematic review and meta-analysis. | 2020 | Clinical Otolaryngology |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| EASL clinical practice guidelines on the management of cystic liver diseases. | 2022 | Journal of Hepatology |
| Evidence-based clinical practice guidelines for liver cirrhosis 2020. | 2021 | Journal of Gastroenterology |
| A pituitary society update to acromegaly management guidelines. | 2021 | Pituitary |
| Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. | 2021 | Journal of the National Comprehensive Cancer Network |
| A consensus statement on acromegaly therapeutic outcomes. | 2018 | Nature |